About the Company
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACRX News
8-K: ACELRX PHARMACEUTICALS INC
Item 1.01 Entry into a Material Definitive Agreement. Asset Purchase Agreement On March 12, 2023, AcelRx Pharmaceuticals, Inc., or AcelRx, entered into an Asset Purchase Agreement, or the Purchase ...
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
March 14, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Analysts Recommend Holding Your Position In AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX)
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) price closed lower on Tuesday, March 14, dropping -21.05% below its previous close. A look at the daily price movement shows that the last close reads $1.10, ...
ACRX AcelRx Pharmaceuticals, Inc.
The chart has 1 X axis displaying Time. Data ranges from 2022-03-16 00:00:00 to 2023-03-17 18:18:25. The chart has 1 Y axis displaying values. Data ranges from -90.78 to 6.28.
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
March 1, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for ...
AcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRX
Shares of AcelRx Pharmaceuticals Inc. jumped sharply in premarket trading Tuesday after the specialty pharmaceutical company unveiled plans to sell its Dsuvia pain drug and prioritize its ...
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's ...
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
March 1, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use ...
Loading the latest forecasts...